Bank of America Corp DE Increases Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Bank of America Corp DE boosted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 45.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 95,160 shares of the specialty pharmaceutical company's stock after buying an additional 29,584 shares during the period. Bank of America Corp DE owned approximately 0.45% of ANI Pharmaceuticals worth $5,260,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. increased its position in ANI Pharmaceuticals by 14.6% during the 4th quarter. Ameriprise Financial Inc. now owns 271,805 shares of the specialty pharmaceutical company's stock valued at $15,025,000 after buying an additional 34,586 shares in the last quarter. Freestone Grove Partners LP bought a new position in ANI Pharmaceuticals during the 4th quarter valued at approximately $259,000. Northern Trust Corp increased its position in ANI Pharmaceuticals by 9.0% during the 4th quarter. Northern Trust Corp now owns 204,345 shares of the specialty pharmaceutical company's stock valued at $11,296,000 after buying an additional 16,820 shares in the last quarter. Aquatic Capital Management LLC increased its holdings in shares of ANI Pharmaceuticals by 149.6% in the 4th quarter. Aquatic Capital Management LLC now owns 6,740 shares of the specialty pharmaceutical company's stock worth $373,000 after purchasing an additional 4,040 shares in the last quarter. Finally, Oberweis Asset Management Inc. increased its holdings in shares of ANI Pharmaceuticals by 50.8% in the 4th quarter. Oberweis Asset Management Inc. now owns 65,600 shares of the specialty pharmaceutical company's stock worth $3,626,000 after purchasing an additional 22,100 shares in the last quarter. Institutional investors own 76.05% of the company's stock.

Insider Activity at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the transaction, the vice president now directly owns 80,145 shares in the company, valued at approximately $5,526,799.20. The trade was a 0.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christopher Mutz sold 4,000 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total value of $241,800.00. Following the transaction, the insider now owns 107,317 shares in the company, valued at $6,487,312.65. This trade represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,681 shares of company stock worth $408,498. Corporate insiders own 11.10% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Wall Street Zen lowered ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Truist Financial lifted their target price on ANI Pharmaceuticals from $62.00 to $65.00 and gave the stock a "hold" rating in a report on Monday, April 21st. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 target price for the company. JPMorgan Chase & Co. assumed coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price for the company. Finally, Guggenheim reissued a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a report on Monday, May 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $80.13.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock traded up $1.00 on Friday, reaching $59.26. The stock had a trading volume of 285,484 shares, compared to its average volume of 305,343. The stock has a market cap of $1.28 billion, a P/E ratio of -107.75 and a beta of 0.56. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $77.00. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The company has a 50 day simple moving average of $65.81 and a 200 day simple moving average of $60.76.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. The firm had revenue of $197.12 million for the quarter, compared to the consensus estimate of $179.75 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The company's revenue for the quarter was up 43.4% on a year-over-year basis. During the same period last year, the business posted $0.82 EPS. Equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.